GFAP and brain injury: These same biomarkers are also of interest in traumatic brain injury (TBI), which is recognized as a modifiable risk factor for dementia,2 and where glial fibrillary acidic protein (GFAP), in combination with ubiquitin carboxyl‐terminal hydrolase L1 (UCHL1), is cleared for clinical use in the acute injury setting.